MacroGenics (MGNX) Aktievy
MacroGenics, Inc. är ett biofarmaceutiskt företag i klinisk fas som upptäcker, utvecklar, tillverkar och kommersialiserar antikroppsbaserade läkemedel för behandling av cancer i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
MGNX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MacroGenics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$3.52 |
| 52 veckors högsta | US$3.88 |
| 52 veckors lägsta | US$1.19 |
| Beta | 1.08 |
| 1 månads förändring | -2.22% |
| 3 månaders förändring | 104.65% |
| 1 års förändring | 128.57% |
| 3 års förändring | -42.01% |
| 5 års förändring | -88.56% |
| Förändring sedan börsintroduktionen | -85.91% |
Senaste nyheter och uppdateringar
Analysuppdatering • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Analysuppdatering • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking AlphaRecent updates
Analysuppdatering • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Analysuppdatering • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking AlphaAnalysartikel • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
Analysuppdatering • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.Analysartikel • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...Analysuppdatering • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.Analysartikel • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...Analysartikel • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analysartikel • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
Ny analys • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.Analysartikel • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking AlphaAnalysartikel • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analysartikel • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analysartikel • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking AlphaAnalysartikel • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking AlphaAnalysartikel • Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
With a price-to-sales (or "P/S") ratio of 5.4x MacroGenics, Inc. ( NASDAQ:MGNX ) may be sending very bullish signals at...Aktieägarnas avkastning
| MGNX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 11.7% | 0.1% | 2.6% |
| 1Y | 128.6% | 35.5% | 26.2% |
Avkastning vs industri: MGNX översteg US Biotechs branschen som gav 35.5 % under det senaste året.
Avkastning vs Marknaden: MGNX översteg US marknaden som gav 26.2 % under det senaste året.
Prisvolatilitet
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: MGNX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: MGNX s veckovolatilitet ( 17% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2000 | 293 | Eric Risser | www.macrogenics.com |
MacroGenics, Inc. är ett biofarmaceutiskt företag i klinisk fas som upptäcker, utvecklar, tillverkar och kommersialiserar antikroppsbaserade läkemedel för behandling av cancer i USA. Bolagets produktportfölj omfattar lorigerlimab, en bispecifik DART-molekyl som riktar sig mot checkpointhämmarna PD-1 och CTLA-4 för behandling av mCRPC och docetaxel, som befinner sig i klinisk fas 2-studie, samt för behandling av platinumresistent äggstockscancer och klarcellig gynekologisk cancer, som har slutfört klinisk fas 1-studie; MGC026, en ADC som riktar sig mot B7-H3 och levererar en ny topoisomeras I-hämmare (TOP1i)-baserad linker-payload; MGC028, en antikropps-läkemedelskonjugat (ADC) som riktar sig mot ADAM9 och levererar en ny TOP1i-baserad linker-payload för behandling av solida tumörer, som befinner sig i kliniska fas 1-studier; MGC030, en ADC-molekyl som riktar sig mot ett icke tillkännagivet antigen som uttrycks i flera solida tumörer, som befinner sig i prekliniska studier. Bolaget utvecklar också program för T-cellsengagemang.
MacroGenics, Inc. Sammanfattning av grunderna
| MGNX grundläggande statistik | |
|---|---|
| Börsvärde | US$187.50m |
| Vinst(TTM) | -US$74.62m |
| Intäkter(TTM) | US$149.50m |
1.5x
P/S-förhållande-3.0x
P/E-förhållandeÄr MGNX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MGNX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$149.50m |
| Kostnad för intäkter | US$183.18m |
| Bruttovinst | -US$33.68m |
| Övriga kostnader | US$40.94m |
| Intäkter | -US$74.62m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.17 |
| Bruttomarginal | -22.53% |
| Nettovinstmarginal | -49.91% |
| Skuld/egenkapitalförhållande | 0% |
Hur har MGNX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/12 02:35 |
| Aktiekurs vid dagens slut | 2026/05/12 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
MacroGenics, Inc. bevakas av 17 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |